Meeting
Abstract Number: 111
Hospital Medicine 2020, Virtual Competition
Background: Factor concentrates such as 4 factor-prothrombin complex concentrate (4F-PCC) are commonly used off-label as reversal agents in factor Xa inhibitor-associated bleeding events. However, there have been limited studies on the efficacy and safety of 4F-PCC use in these settings. We conducted a retrospective observational study of the use of 4F-PCC for major bleeding occurring […]
Abstract Number: 156
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: While anticoagulants are the core treatment plan for preventing strokes in patients with atrial fibrillation and managing patients with thromboembolic disease, there is a dichotomy of efficacy and harm with their use. Rapid inpatient reversal protocols are important for patient safety. Four factor prothrombin complex concentrate (4FPCC) is approved for reversal of warfarin-induced coagulopathy. […]
Abstract Number: 266
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Strategies to reverse the effect of warfarin, a vitamin K antagonist (VKA), may be necessary for patients who are actively bleeding, asymptomatic with markedly elevated INR values, or requiring urgent invasive procedures. The purpose of this quality improvement activity (QIA) was to evaluate adherence to the 2012 CHEST guidelines for use of vitamin K […]